Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Comparative Analysis of Direct Oral Anticoagulants in Atrial Fibrillation
Author(s): Ton Duy Mai , Tri Huynh Quang Ho , Sy Van Hoang , et al Added: 1 week ago

Anticoagulation

Electrophysiology & Arrhythmia
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 10 months ago

Anticoagulation

Prevention & Chronic Conditions
Anticoagulant Use in Older Adults
Author(s): Monika Bhandari , Akshyaya Pradhan , Pravesh Vishwakarma , et al Added: 3 months ago

Anticoagulation

Electrophysiology & Arrhythmia
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 8 months ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 1 year ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Felicita Andreotti , Diana Gorog , Marco Valgimigli , et al Start date: Dec 14, 2023
This live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), will demonstrate how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Join key opinion leadersProf Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese (University of Sassari,… View more

Anticoagulation
Author(s): Mario DiazNuila-Alcazar , Daniel Valcárcel-Paz , Pablo Del Castillo-Vásquez , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
AHA 24: The OPTION Trial
Author(s): Oussama M Wazni Added: 5 months ago
AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).OPTION is a prospective, multi-center, multi… View more

Anticoagulation

Electrophysiology & Arrhythmia
ESC 23: The PUSH-AHF Study
Author(s): Paulus Kirchhof Added: 1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,… View more

Anticoagulation

Heart Failure